Compare · STEX vs TMDX
STEX vs TMDX
Side-by-side comparison of Streamex Corp. (STEX) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both STEX and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $2.62B, about 52.3x STEX ($50.1M).
- Over the past year, STEX is down 92.8% and TMDX is down 33.8% - TMDX leads by 59.0 points.
- STEX has been more active in the news (11 items in the past 4 weeks vs 2 for TMDX).
- TMDX has more recent analyst coverage (20 ratings vs 1 for STEX).
- Company
- Streamex Corp.
- TransMedics Group Inc.
- Price
- $0.41-5.38%
- $76.58+1.57%
- Market cap
- $50.1M
- $2.62B
- 1M return
- -33.96%
- -12.43%
- 1Y return
- -92.80%
- -33.79%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 11
- 2
- Recent ratings
- 1
- 20
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest STEX
- Streamex Corp Announces GLDY Now Available for Custody by CNB Custody - a Division of Community National Bank, Further Expanding Custody Options for GLDY
- SEC Form 8-K filed by Streamex Corp.
- SEC Form 4 filed by Streamex Corp.
- SEC Form 4 filed by Streamex Corp.
- Streamex Corp. to Present at the ThinkEquity Conference on October 15, 2026
- Streamex CEO Henry McPhie to Embark on Asia Tour with Events in Singapore and Hong Kong
- Streamex Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Streamex Co-Founder Morgan Lekstrom to Transition to Independent Director
- Streamex Corp. Announces Institutional Investment into Strategy Built Around GLDY
- Streamex Corp. to Participate in the Lytham Partners Fall 2026 Investor Conference
Latest TMDX
- Barclays initiated coverage on TransMedics Group with a new price target
- SEC Form 3 filed by new insider Araujo Fernando N.
- Director Weill David bought $109,058 worth of shares (1,336 units at $81.63), increasing direct ownership by 9% to 16,392 units (SEC Form 4)
- TransMedics Group Inc. filed SEC Form 8-K: Regulation FD Disclosure
- TransMedics Appoints Fernando Araujo as Chief Financial Officer and Reiterates 2026 Financial Outlook
- TransMedics to Present at Upcoming September Investor Conferences
- Director Tobin James R gifted 18,000 shares (SEC Form 4)
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Second Quarter 2026 Financial Results